Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen Ø, Denmark; Statens Serum Institut, Department of Infectious Disease Immunology, Artillerivej 5, 2300 Copenhagen S, Denmark.
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Jagtvej 162, 2100 Copenhagen Ø, Denmark.
Eur J Pharm Biopharm. 2019 Jul;140:29-39. doi: 10.1016/j.ejpb.2019.04.020. Epub 2019 May 2.
Using subunit vaccines, e.g., based on peptide or protein antigens, to teach the immune system to kill abnormal host cells via induction of cytotoxic T lymphocytes (CTL) is a promising strategy against intracellular infections and cancer. However, customized adjuvants are required to potentiate antigen-specific cellular immunity. One strong CTL-inducing adjuvant is the liposomal cationic adjuvant formulation (CAF)09, which is composed of dimethyldioctadecylammonium (DDA) bromide, monomycoloyl glycerol (MMG) analogue 1 and polyinosinic:polycytidylic acid [poly(I:C)]. However, this strong CTL induction requires intraperitoneal administration because the vaccine forms a depot at the site of injection (SOI) after subcutaneous (s.c.) or intramuscular (i.m.) injection, and depot formation impedes the crucial vaccine targeting to the cross-presenting dendritic cells (DCs) residing in the lymph nodes (LNs). The purpose of the present study was to investigate the effect of polyethylene glycol (PEG) grafting of CAF09 on the ability of the vaccine to induce antigen-specific CTL responses after s.c. administration. We hypothesized that steric stabilization and charge shielding of CAF09 by PEGylation may reduce depot formation at the SOI and enhance passive drainage to the LNs, eventually improving CTL induction. Hence, the vaccine (antigen/CAF09) was post-grafted with a novel type of anionic PEGylated peptides based on GDGDY repeats, which were end-conjugated with one or two PEG moieties, resulting in mono- and bis-PEG-peptides of different lengths (10, 15 and 20 amino acid residues). For comparison, CAF09 was also grafted by inclusion of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-methoxy(PEG)-2000 (DSPE-PEG) in the bilayer structure during preparation. Grafting of CAF09 with either type of PEG resulted in charge shielding, evident from a reduced surface charge. Upon s.c. immunization of mice with the model antigen ovalbumin (OVA) adjuvanted with PEGylated CAF09, stronger CTL responses were induced as compared to immunization of mice with unadjuvanted OVA. Biodistribution studies confirmed that grafting of CAF09 with DSPE-PEG improved the passive drainage of the vaccine to LNs, because a higher dose fraction was recovered in DCs present in the draining LNs, as compared to the dose fraction detected for non-PEGylated CAF09. In conclusion, PEGylation of CAF09 may be a useful strategy for the design of an adjuvant, which induces CTL responses after s.c. and i.m. administration. In the present studies, CAF09 grafted with 10 mol% DSPE-PEG is the most promising of the tested adjuvants, but additional studies are required to further elucidate the potential of the strategy.
使用亚单位疫苗,例如基于肽或蛋白抗原的疫苗,来教导免疫系统通过诱导细胞毒性 T 淋巴细胞(CTL)来杀死异常宿主细胞,是一种针对细胞内感染和癌症的很有前途的策略。然而,需要定制佐剂来增强抗原特异性细胞免疫。一种强有力的 CTL 诱导佐剂是脂质阳离子佐剂制剂(CAF)09,它由二甲基二十八烷基溴化铵(DDA)、单酰基甘油(MMG)类似物 1 和聚肌苷酸:聚胞苷酸[聚(I:C)]组成。然而,这种强烈的 CTL 诱导需要腹腔内给药,因为疫苗在皮下(sc)或肌肉内(im)注射后在注射部位(SOI)形成储存库,而储存库的形成阻碍了疫苗对淋巴结(LN)中存在的交叉呈递树突状细胞(DC)的关键靶向作用。本研究的目的是研究 CAF09 的聚乙二醇(PEG)接枝对 sc 给药后疫苗诱导抗原特异性 CTL 反应能力的影响。我们假设 CAF09 的 PEG 化通过空间位阻和电荷屏蔽可以减少 SOI 处的储存库形成,并增强被动引流到 LNs,最终改善 CTL 诱导。因此,疫苗(抗原/CAF09)被新型基于 GDGDY 重复的阴离子 PEG 化肽进行了后接枝,其通过末端共轭连接一个或两个 PEG 部分,得到不同长度(10、15 和 20 个氨基酸残基)的单和双 PEG-肽。为了比较,CAF09 也在制备过程中通过包含 1,2-二硬脂酰-sn-甘油-3-磷酸乙醇胺-N-甲氧基(PEG)-2000(DSPE-PEG)在双层结构中进行接枝。CAF09 的接枝导致电荷屏蔽,从表面电荷的减少可以明显看出。用 PEG 化 CAF09 佐剂的模型抗原卵清蛋白(OVA)免疫小鼠后,与未佐剂的 OVA 免疫的小鼠相比,诱导了更强的 CTL 反应。生物分布研究证实,DSPE-PEG 接枝 CAF09 可改善疫苗向 LNs 的被动引流,因为在引流 LN 中存在的 DC 中回收的剂量分数更高,与检测到的非 PEG 化 CAF09 的剂量分数相比。总之,CAF09 的 PEG 化可能是一种有用的策略,用于设计可皮下和肌肉内给药后诱导 CTL 反应的佐剂。在本研究中,接枝 10 mol% DSPE-PEG 的 CAF09 是测试佐剂中最有前途的,但需要进一步研究来进一步阐明该策略的潜力。